Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1537874 | 0.89 | HTR6 (0.75) | HTR6HTR1ADRD2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL4309916 | 0.88 | HTR6 (0.73) | HTR6HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL1537812 | 0.86 | HTR6 (0.74) | HTR6 | |
| SCHEMBL15655470 | 0.86 | HTR6 (0.77) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL5698346 | 0.86 | HTR6 (0.77) | HTR6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4312376 | 0.85 | HTR6 (0.72) | HTR6 | |
| SCHEMBL4322677 | 0.85 | HTR6 (0.60) | HTR6 | |
| SCHEMBL1136504 | 0.84 | HTR6 (1.00) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL5698316 | 0.84 | HTR6 (0.73) | HTR6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4312546 | 0.84 | HTR6 (0.59) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | claimed |
| EP-1401812-B1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | EP | disclosed |
| US-6790848-B2 | TREATING CENTRAL NERVOUS SYSTEM OR GASTROINTESTINAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-14 | — | — | US | disclosed |
| EP-1401812-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102774-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR3A | HTR6 1/4885CYP3A4 261/4885HTR1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.